Day One Biopharmaceuticals, Inc. (DAWN) Bundle
An Overview of Day One Biopharmaceuticals, Inc. (DAWN)
General Summary of Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc. is a biotechnology company focused on developing therapies for pediatric and young adult cancers. Founded in 2018, the company is headquartered in South San Francisco, California.
Key Products and Services
- Tovorafenib (DAY101): Primary drug for pediatric low-grade glioma
- Pediatric oncology therapeutic development platform
- Precision medicine approach for rare pediatric cancers
Financial Performance (Q4 2023)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $24.7 million |
| Net Loss | $32.1 million |
| Cash and Investments | $351.2 million |
Market Position and Industry Leadership
Key Market Differentiators:
- Exclusive focus on pediatric oncology
- Innovative precision medicine approach
- FDA breakthrough therapy designation for tovorafenib
Clinical Development Highlights
| Clinical Trial | Status | Patient Population |
|---|---|---|
| FIREFLY-1 Trial | Ongoing Phase 2 | Pediatric Low-Grade Glioma |
| Tovorafenib Expanded Access Program | Active | Pediatric Patients |
Corporate Metrics
- Employees: Approximately 130
- Research Locations: South San Francisco, CA
- Public Listing: NASDAQ (DAWN)
Mission Statement of Day One Biopharmaceuticals, Inc. (DAWN)
Mission Statement of Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc. mission statement focuses on transforming pediatric oncology through innovative targeted therapies.
Core Mission Components
| Component | Specific Details | Quantitative Metrics |
|---|---|---|
| Pediatric Cancer Treatment | Developing targeted therapies | 3 clinical-stage oncology programs as of 2024 |
| Research Innovation | Precision medicine approach | $87.4 million R&D investment in 2023 |
| Patient Impact | Addressing unmet medical needs | Treating rare pediatric cancer subtypes |
Research and Development Focus
- Total pipeline of 4 therapeutic candidates
- Concentration on genetically defined pediatric cancers
- Advanced molecular targeting technologies
Therapeutic Portfolio
| Drug Candidate | Cancer Type | Clinical Stage |
|---|---|---|
| DAY101 | Pediatric Low-Grade Glioma | Phase 2 Clinical Trial |
| DAY301 | Neuroblastoma | Preclinical Development |
Financial Commitment
2023 financial metrics demonstrating mission alignment:
- Research Expenditure: $87.4 million
- Cash and Investments: $362.1 million
- Net Loss: $96.3 million
Strategic Objectives
Primary Goal: Develop transformative targeted therapies for pediatric cancer patients with limited treatment options.
Vision Statement of Day One Biopharmaceuticals, Inc. (DAWN)
Vision Statement of Day One Biopharmaceuticals, Inc. (DAWN)
Strategic Vision for Pediatric Oncology InnovationDay One Biopharmaceuticals, Inc. (DAWN) focuses on developing targeted therapies for pediatric cancer patients. As of Q4 2023, the company's vision centers on transforming pediatric cancer treatment through precision medicine.
Key Vision Components
Research and Development FocusThe company's vision emphasizes breakthrough therapeutic approaches for rare pediatric cancer types. Specific research targets include:
- Molecular targeted therapies
- Precision oncology platforms
- Genomic-informed treatment strategies
Clinical Development Metrics
| Metric | 2024 Status |
|---|---|
| Active Clinical Trials | 7 ongoing pediatric cancer trials |
| Pipeline Development Stage | 3 drug candidates in Phase 1/2 trials |
| Research Investment | $42.3 million R&D budget |
DAWN's vision prioritizes patient outcomes with a focus on:
- Minimal treatment side effects
- Personalized therapeutic strategies
- Improved long-term survival rates
Collaborative Research Ecosystem
| Collaboration Type | Number of Partnerships |
|---|---|
| Academic Institutions | 12 research collaborations |
| Pharmaceutical Partners | 5 strategic alliances |
| Cancer Research Centers | 8 active research networks |
Market capitalization as of January 2024: $687.4 million
Cash and cash equivalents: $213.6 million
Core Values of Day One Biopharmaceuticals, Inc. (DAWN)
Core Values of Day One Biopharmaceuticals, Inc. (DAWN)
Patient-Centered Innovation
Day One Biopharmaceuticals focuses on developing targeted therapies for pediatric and young adult cancer patients.
| Metric | Value |
|---|---|
| R&D Investment in 2023 | $67.4 million |
| Clinical Trials in Pediatric Oncology | 4 active trials |
Scientific Excellence
Commitment to rigorous scientific research and development.
- Proprietary drug development platform
- Collaboration with leading research institutions
- Advanced molecular targeting technologies
Transparency and Integrity
Maintaining highest standards of corporate and scientific transparency.
| Compliance Metric | Performance |
|---|---|
| FDA Interactions in 2023 | 12 formal communications |
| Clinical Trial Disclosure Rate | 100% |
Collaborative Approach
Building strategic partnerships across pharmaceutical and research ecosystems.
- Academic research collaborations
- Industry partnership programs
- Global research network engagement
Commitment to Unmet Medical Needs
Targeting rare and difficult-to-treat pediatric cancer indications.
| Focus Area | Current Status |
|---|---|
| Rare Pediatric Cancer Indications | 3 primary research programs |
| Orphan Drug Designations | 2 active designations |
Day One Biopharmaceuticals, Inc. (DAWN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.